Predict your next investment

Corporation
santeninc.com

See what CB Insights has to offer

Investments

1

Portfolio Exits

1

Partners & Customers

4

About Santen

Santen is the U.S. subsidiary of Santen Pharmaceutical Co. Santen researches, develops, and markets ophthalmic products worldwide. Santen Pharmaceutical has subsidiaries in the U.S., Europe, and Asia, including its wholly owned California-based subsidiary, Santen, which includes the Global Clinical Development and Medical Affairs organization. Santen also maintains a satellite business development office in Irvine, California, which provides direct access to the cluster of ophthalmic companies operating in that area. Santen holds the top share within the Japanese and Chinese markets and is one of the leading ophthalmic companies worldwide. Santen's global product pipeline includes a number of prescription pharmaceuticals in varying clinical trial phases.

Santen Headquarter Location

2100 Powell Street suite 1600

Emeryville, California, 94608,

United States

415-268-9100

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Santen News

Contact lens substitution can cause discomfort, adverse events

Oct 25, 2021

Disclosures: Jones reports that he or the Centre for Ocular Research & Education has received research support or lecture honoraria from Alcon, Allergan, CooperVision, GL Chemtec, iMed Pharma, Johnson & Johnson Vision, Lubris, Menicon, Nature’s Way, Novartis, Ote, PS Therapy, Safilens, Santen, Shire, SightGlass and Visioneering. Jones also reports consulting and/or serving on an advisory board for Alcon, CooperVision, Johnson & Johnson Vision, Novartis and Ophtecs. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Few soft contact lens types perform identically in the clinical setting, so substitution of a prescribed lens can result in patient dissatisfaction and adverse events, according to a review article in Contact Lens and Anterior Eye. “[As practitioners and researchers], we were concerned that there was growing support, particularly since the pandemic, toward buying things online,” co-author Lyndon Jones, BSc, PhD, DSc, FCAHS, FCOptom, DipCLP, DipOrth, FAAO, FIACLE, FBCLA, professor at University of Waterloo and director of the Centre for Ocular Research & Education, told Healio Optometry. Online contact lens sellers may substitute cheaper lenses for those that were prescribed, Jones said. “Some patients can pretty much wear anything, but the majority of patients have been prescribed a particular lens, particular replacement period and particular material and design because that’s the one that works best with their ocular surface,” Jones said. He said he put together a group of well-respected practitioners and researchers to conduct an evidence-based review, systematically selecting 16 lens properties for which, “if you were to not prescribe that particular element, there is a potential opportunity for things to go awry,” Jones said. Lyndon Jones According to the study, the parameters were surface treatment, internal wetting agent, oxygen permeability, water content, modulus, total diameter, back optic zone radius, thickness, edge profile, back surface design, optical design, power, tint, UV protection, wearing modality and replacement frequency. Jones and colleagues wrote that their objective was to present evidence from contact lens literature to show “why all contact lenses are not the same and to consider the potential consequences of inappropriate lens substitution.” Jones said that the researchers were surprised by the number of studies “that actually supported the fact that substitution without consultation can produce complications.” “Given the wide range of parameters and properties available, few soft contact lenses are identical in their clinical performances,” the researchers said. They concluded that substitution of 15 out of 16 of the properties evaluated resulted in between one and six potential aspects of patient dissatisfaction and adverse events. The only exception was back surface design. “Probably the reason for that is that very few companies actually disclose what their back surface designs are,” Jones told Healio. “Some of these [online supply] companies may come back and say they’ve done substitution, and the patients have been OK,” he said. “But how do you know they’re OK? Are they still wearing the lenses? How do you know their wearing time didn’t go down or that they weren’t as comfortable at the beginning of the month as they were at the end of the month? You don’t know because you’re not collecting the data.” Jones said some patients may have “eyes like concrete,” but not the majority. “We’ve had situations where companies have made incredibly small changes to a lens design and perhaps tweaked the edge format or made a tiny change to the midperipheral thickness or something apparently as inconsequential as changing the engraving on the lens that shows whether or not it’s inside out — and some patients know it, as they are incredibly impacted by even the most subtle change,” he said. Read more about

Santen Investments

1 Investments

Santen has made 1 investments. Their latest investment was in Clearside Biomedical as part of their Series A - II on January 1, 2013.

CBI Logo

Santen Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/31/2013

Series A - II

Clearside Biomedical

$7.9M

Yes

4

Date

1/31/2013

Round

Series A - II

Company

Clearside Biomedical

Amount

$7.9M

New?

Yes

Co-Investors

Sources

4

Santen Portfolio Exits

1 Portfolio Exit

Santen has 1 portfolio exit. Their latest portfolio exit was Clearside Biomedical on June 02, 2016.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/2/2016

IPO

$991

4

Date

6/2/2016

Exit

IPO

Companies

Valuation

$991

Acquirer

Sources

4

Santen Partners & Customers

4 Partners and customers

Santen has 4 strategic partners and customers. Santen recently partnered with Oxford BioMedica on June 6, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

6/26/2019

Partner

Oxford BioMedica

United Kingdom

2

6/13/2017

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

1/11/2016

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

5/28/2014

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

6/26/2019

6/13/2017

1/11/2016

5/28/2014

Type

Partner

Partner

Licensor

Partner

Business Partner

Oxford BioMedica

Country

United Kingdom

Subscribe to see more

Subscribe to see more

Subscribe to see more

News Snippet

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

Santen Team

1 Team Member

Santen has 1 team member, including former Senior Director, Rajat N Agrawal.

Name

Work History

Title

Status

Rajat N Agrawal

Senior Director

Former

Name

Rajat N Agrawal

Work History

Title

Senior Director

Status

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.